The biggest fallers on the FTSE 100 were Schroders, down 12p to 371.6p, IAG, down 8.9p to 338.5p, AstraZeneca, down 256p to ...

Ascendis Pharma beat Q4 earnings and revenue estimates, driven by a $100M Novo Nordisk deal and Yorvipath's EU launch.

Royalty Pharma has signed a deal to pay Biogen $250m to support the development of its late-stage experimental lupus ...

As the Q4 2024 pharma earnings period rolls on through the first month of President Donald Trump’s second term, executives ...

Portfolio Receipts of $742 million in Q4 2024 and $2,801 million for FY 2024Royalty Receipts growth of 12% in Q4 2024 and 13% for FY 2024 Net cash provided by operating activities of $743 million in ...

Portfolio Receipts of $742 million in Q4 2024 and $2,801 million for FY 2024Royalty Receipts growth of 12% in Q4 2024 and 13% for FY 2024 Net ...

Amazon Music and WPP unveiled Louder Than Cancer, an effort uniting top global artists to harness the power of music in recognition of World Cancer Day with creative leadership from WPP’s Grey Health, ...

If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.

Q4 2024 Earnings Call Transcript February 6, 2025 AstraZeneca PLC misses on earnings expectations. Reported EPS is $1.05 EPS, ...

AstraZeneca PLC (AZN) reports a robust 21% revenue increase for 2024, while navigating market challenges and strategic ...

AstraZeneca stock rose early Thursday after the drugmaker beat fourth-quarter earnings views and delivered upbeat guidance.